Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

137.71USD
10:33pm IST
Change (% chg)

$4.28 (+3.21%)
Prev Close
$133.43
Open
$133.85
Day's High
$137.89
Day's Low
$133.30
Volume
173,694
Avg. Vol
858,158
52-wk High
$145.29
52-wk Low
$96.18

ALXN.OQ

Chart for ALXN.OQ

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $29,779.61
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): 57.82 30.66 31.86
EPS (TTM): 2.31 -- --
ROI: 4.17 14.54 14.08
ROE: 6.11 15.62 15.39

BRIEF-Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027

* Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027

16 Aug 2017

BRIEF-Third Point LLC takes share stake in Blackrock Inc, Alexion Pharmaceuticals

* Third Point LLC takes share stake of 1.6 million shares in Blackrock Inc - SEC filing‍​

12 Aug 2017

Alexion posts higher second-quarter earnings on strong Soliris sales

NEW YORK Alexion Pharmaceuticals Inc posted a better than expected second-quarter profit on Thursday and raised its full-year forecast on strong sales of its expensive rare disease treatment Soliris.

27 Jul 2017

Alexion posts higher Q2 earnings on strong Soliris sales

NEW YORK, July 27 Alexion Pharmaceuticals Inc posted a better than expected second-quarter profit on Thursday and raised its full-year forecast on strong sales of its expensive rare disease treatment Soliris.

27 Jul 2017

BRIEF-Arbutus announces conclusion of LNP license agreement with Alexion

* Arbutus announces conclusion of LNP license agreement with Alexion

27 Jul 2017

BRIEF-Blueprint Medicines to evaluate advance disease discovery program opportunities

* Blueprint Medicines to evaluate opportunities to advance rare disease discovery program in fibrodysplasia ossificans progressiva following discontinuation of collaboration with Alexion

27 Jul 2017

BRIEF-Alexion reaches funding agreement with NICE and NHS England for Strensiq

* Says has reached national funding agreement with NICE & NHS England based on Managed Access Agreement

05 Jul 2017

BRIEF-Alexion receives positive CHMP opinion for Soliris in the EU

* Alexion receives positive CHMP opinion for Soliris (eculizumab) for the treatment of patients with refractory Generalized Myasthenia Gravis (GMG) in the European Union

23 Jun 2017

REFILE-Alexion names Biogen's Paul Clancy as CFO

June 13 Alexion Pharmaceuticals Inc on Tuesday named Biogen Inc's Chief Financial Officer Paul Clancy as its finance head, effective July 31.

14 Jun 2017

BRIEF-Alexion Pharmaceuticals in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million

* Alexion Pharmaceuticals Inc - in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million

14 Jun 2017

Competitors

Earnings vs. Estimates